Prognostic Impact of Peripheral Blood T-Cell Subsets at the Time of Diagnosis on Survival in Patients with Diffuse Large B-Cell Lymphoma
- 1 July 2021
- journal article
- research article
- Published by S. Karger AG in Acta Haematologica
- Vol. 144 (4), 427-437
- https://doi.org/10.1159/000510912
Abstract
Introduction: The effects of lymphocyte subtypes, including helper (Th), natural killer (NK), and regulatory (Treg) cells, and other T-cell subtypes on treatment outcomes in diffuse large B-cell lymphoma (DLBCL) patients are not clearly established. Methods: Among 151 consecutive patients diagnosed with DLBCL, we collected peripheral blood samples at diagnosis from 91 patients who received at least 1 cycle of R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab) chemotherapy and analyzed lymphocyte subsets by flow cytometry. Results: DLBCL patients had a higher proportion of CD4(+)CD25(+) Treg (p < 0.001) and lower absolute lymphocyte count than those of healthy controls. Lymphopenia at diagnosis was associated with advanced-stage disease (p = 0.001), a high-intermediate/high-risk International Prognostic Index (IPI) (p < 0.001), and older age (p = 0.060). High-intermediate/high-risk IPI, high proportion of CD3(+)CD4(+) Th cells, and extranodal site >= 2 correlated with unfavorable prognostic factors for survival. High proportion of Th cells was associated with fewer cytotoxic T cells and NK cells at the time of diagnosis. Conclusion: This study showed an association between circulating lymphocyte subsets including Th cells, Tregs, and NK cells and clinical outcomes in DLBCL; however, further confirmation is needed via prospective trials.Keywords
This publication has 23 references indexed in Scilit:
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab EraJournal of Clinical Oncology, 2010
- Rituximab: Mechanism of ActionSeminars in Hematology, 2010
- Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapyAnnals Of Oncology, 2009
- Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B‐cell lymphoma and suggests patients’ survival benefit from rituximabEuropean Journal of Haematology, 2008
- Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphomaBritish Journal of Haematology, 2008
- Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphomaLeukemia, 2007
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2006
- Optimal Use of Prognostic Factors in Non-Hodgkin LymphomaHematology-American Society Hematology Education Program, 2006
- Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T CellsThe Journal of Experimental Medicine, 2004